OssDsign (DB:5J6) - Aandelenkoers, Nieuws & Analyse

5J6 Overzicht aandelen

5J6 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 24.94% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 33.3% zal stijgen

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( €879M )

OssDsign AB (publ) Concurrenten

Paul Hartmann

DB:PHH2

€745.9m

VITA 34

XTRA:V3V

€71.8m

LIMES Schlosskliniken

XTRA:LIK

€97.9m

PULSION Medical Systems

MUN:PUS

€133.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor OssDsign
Historische aandelenkoersen
Huidige aandelenkoers	SEK 0.73
52 Week Hoogtepunt	SEK 0.91
52 Week Laag	SEK 0.47
Bèta	0.84
11 maand verandering	37.71%
3 maanden verandering	20.72%
1 Jaar Verandering	20.72%
33 jaar verandering	-10.38%
5 jaar verandering	n/a
Verandering sinds IPO	-49.55%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	5J6	DE Medical Equipment	DE Markt
7D	15.6%	3.2%	0.9%
1Y	20.7%	-6.5%	7.7%

Rendement versus industrie: 5J6 overtrof de German Medical Equipment industrie, die het afgelopen jaar een rendement -6.5 % opleverde.

Rendement versus markt: 5J6 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 7.7 %.

Prijsvolatiliteit

Is 5J6's price volatile compared to industry and market?
5J6 volatility
5J6 Average Weekly Movement	16.3%
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 5J6 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van 5J6 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	25	Morten Henneveld	www.ossdsign.com

OssDsign AB (publ) ontwerpt, produceert en verkoopt implantaten en materiaaltechnologie voor botregeneratie in Zweden, Duitsland, de Verenigde Staten, het Verenigd Koninkrijk, de rest van Europa en internationaal. Het bedrijf biedt OssDsign Catalyst aan, een nanosynthetisch bottransplantaat dat wordt gebruikt om de botgroei te stimuleren bij ruggengraatfusies. Het bedrijf is opgericht in 2011 en het hoofdkantoor is gevestigd in Uppsala, Zweden.

OssDsign AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van OssDsign zich tot de beurswaarde?
5J6 fundamentele statistieken
Marktkapitalisatie	€76.26m
Inkomsten(TTM)	-€7.85m
Inkomsten(TTM)	€11.06m

6.9x

P/S-verhouding

-9.7x

Koers/Winstverhouding

Is 5J6 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
5J6 resultatenrekening (TTM)
Inkomsten	SEK 127.49m
Kosten van inkomsten	SEK 14.48m
Brutowinst	SEK 113.01m
Overige uitgaven	SEK 203.45m
Inkomsten	-SEK 90.44m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 04, 2025

Winst per aandeel (EPS)	-0.93
Brutomarge	88.64%
Nettowinstmarge	-70.94%
Schuld/Eigen Vermogen Verhouding	0.2%

Hoe presteerde 5J6 op de lange termijn?

Bekijk historische prestaties en vergelijking

5J6 Overzicht aandelen

Beloningen

Risicoanalyse

OssDsign AB (publ) Concurrenten

DB:PHH2

€745.9m

XTRA:V3V

€71.8m

XTRA:LIK

€97.9m

MUN:PUS

€133.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023)

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

Recent updates

Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023)

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share